Arcturus Therapeutics Holdings Inc

ARCT is entrenched in a Stage 4 decline with sequential lower highs and lows and persistent selling pressure. Price remains below down-sloping 9/21/50 EMAs and the 50/200 DMAs, and recent tests into the EMA band have been rejected. Oversold conditions show no exhaustion, reinforcing bearish momentum. With no mean-reversion eligibility and a Speculative strategy focus on clear structural asymmetry, execution now into the EMA resistance zone aligns with optimal risk-reward on the downside.

• ↑ARCT-032 CF program entering Phase II 12-week study in H1 2026
• ↑Cash balance of $213.4M funds operations through 2028
• ↓Q1 2026 net loss of $0.95/sh and zero quarterly revenue